EditorialExploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis☆
Section snippets
Financial support
Grant support received: U01 AA021788 – Treat Mayo (Shah – PI).
Conflict of interest
VS reports personal fees from Novartis Pharmaceuticals, Durect Corporation, Merck Research Laboratories, Afimmune Ltd., outside the submitted work. The other authors have no conflicts of interest.
Please refer to the accompanying ICMJE disclosure forms for further details.
References (20)
- et al.
Corticosteroid therapy of alcoholic hepatitis
Gastroenterology
(1978) - et al.
Alcoholic hepatitis: current challenges and future directions
Clin Gastroenterol Hepatol
(2014) - et al.
Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases
Curr Opin Pharmacol
(2017) - et al.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Lancet
(2015) - et al.
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Lancet
(2018) - et al.
Prednisolone or pentoxifylline for alcoholic hepatitis
N Engl J Med
(2015) - et al.
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice
J Clin Invest
(2012) - et al.
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
Hepatology
(2014) - et al.
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis
N Engl J Med
(2016)
Cited by (12)
Current and emerging therapies for alcohol-associated hepatitis
2023, Liver ResearchAntarctic krill oil ameliorates liver injury in rats exposed to alcohol by regulating bile acids metabolism and gut microbiota
2022, Journal of Nutritional BiochemistryCitation Excerpt :On the other hand, the activation of intestinal FXR can induce intestine cells to secrete FGF15 [53]. FGF15 is an endocrine gastrointestinal hormone that binds FGFR4 in the liver, suppresses the hepatocyte expression of CYP7A1, and inhibits BAs synthesis, thereby creating a negative feedback loop [54]. The decreased activity of FXR in enterocytes of the terminal ileum caused by alcohol intake resulted in less FGF15 protein in the ileum and increased hepatic CYP7A1 protein expression, which likely contributed to increased total plasma and hepatic BAs after chronic ethanol feeding [9].
Emerging Therapies for Alcoholic Hepatitis
2021, Clinics in Liver DiseaseCitation Excerpt :They bind to bile acid, producing fibroblast growth factor 19, which plays a role in negative feedback controlling of bile acid synthesis, decreasing fatty acid synthesis, and promoting fatty acid oxidation in the liver. Moreover, FXR agonist showed anti-inflammatory activity, antioxidant activity, and hepatic hemodynamic benefits, with an improvement in portal hypertension in animal studies.55–57 Obeticholic acid (OCA) is an FXR agonist and a semisynthetic derivative of the chenodeoxycholic acid; it was studied in patients with primary biliary cholangitis and nonalcoholic steatohepatitis (NASH), showing promising efficacy.58,59
Acute Alcoholic Hepatitis
2019, Clinics in Liver DiseaseCitation Excerpt :The FXR agonist obeticholic acid, approved for primary biliary cholangitis, was recently issued a boxed warning by the US Food and Drug Administration for deaths linked to inappropriate dosing in patients with hepatic impairment (Child class B or C or patients with prior hepatic decompensation). Although even patients with moderate AH may meet these criteria, a highly anticipated phase II trial in moderate AH is currently on hold.58 Abstinence from alcohol is the cornerstone of AH treatment.
The Mexican consensus on alcoholic hepatitis
2020, Revista de Gastroenterologia de MexicoUnraveling the Complex Interplay between Epigenetics and Immunity in Alcohol-Associated Liver Disease: A Comprehensive Review
2023, International Journal of Biological Sciences
- ☆
Guest Editor: Didier Samuel.